We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

PERKIN ELMER CORPORATION

PerkinElmer provides detection technologies to detect and identify diseases, imaging technologies to help visualize s... read more Featured Products: More products

Download Mobile App





PerkinElmer’s EUROIMMUN Presents Novel Ultrafast Automated Microscope and Intelligent Software for State-of-the-Art Diagnostics

By LabMedica International staff writers
Posted on 21 Jun 2021
Print article
Image: EUROPattern Microscope Live (Photo courtesy of PerkinElmer, Inc.)
Image: EUROPattern Microscope Live (Photo courtesy of PerkinElmer, Inc.)
EUROIMMUN, a PerkinElmer, Inc. (Waltham, MA; USA) company, presented its novel ultrafast automated microscope and intelligent software for state-of-the-art diagnostics at Medlab Middle East 2021.

The company’s portfolio encompasses indirect immunofluorescence assays (IFA), ELISAs, immunoblots, radioimmunoassays, chemiluminescence immunoassays (ChLIA) and molecular genetic test systems and spans over a thousand diagnostic parameters. At this year’s edition of Medlab Middle East, EUROIMMUN introduced its newly-launched EUROPattern Microscope Live (EPML), a compact immunofluorescence microscope available with the fourth generation of the company’s well-established EUROLabOffice 4.0 (ELO 4.0) laboratory management software. The combined system of hardware and software allows for ultrafast automated immunofluorescence image acquisition, pattern recognition and titer estimation as well as modern diagnostics at the screen.

Due to application of a novel laser focusing technology, the EPML acquires and interprets high quality immunofluorescence images in less than two seconds per image. The system autonomously evaluates a particularly high number of recorded immunofluorescence patterns that are indicative of the presence of certain autoantibodies, and thus point to a specific autoimmune disease, such as rheumatoid arthritis, systemic lupus erythematosus, vasculitis or autoimmune hepatitis. In addition to the positive/negative classification for a variety of different substrates, the patterns of anti-nuclear antibodies (in conformity with the International Consensus on Antinuclear Antibody Patterns) and anti-neutrophil cytoplasmic antibodies can also be recognized by leveraging deep learning algorithms. A touch screen allows easy live microscopy via multi-touch navigation and pinch-to-zoom functionality.

ELO 4.0 software further simplifies and is designed to speed up not only IIFT testing but also other laboratory diagnostics by acting as the central interface for all laboratory instruments, working places and laboratory information systems. ELO 4.0 software enables intelligent and intuitive data management as well as the seamless communication needed to provide operators with a 360-degree view of a patient’s results, including current and past findings, that can lead to a faster, more reliable diagnosis.

In addition, EUROIMMUN showcased its comprehensive test and automation portfolio of CE-marked tests for direct and indirect detection of SARS-CoV-2, including its PCR-based tests EURORealTime SARS-CoV-2 and EURORealTime SARS-CoV-2 / Influenza A / B as well as the SARS-CoV-2 Antigen ELISA.

Related Links:
PerkinElmer, Inc.

New
Gold Supplier
Auto Urinary Sediment Analyzer
EH-2030
New
Gold Supplier
Clinical Chemistry Analyzer
KROMA
New
Multichannel Adjustable-Volume Pipettor
Cole-Parmer Essentials
New
Microbiology IVD System
MALDI Biotyper Sirius One

Print article

Channels

Molecular Diagnostics

view channel
Image: A new blood test could noninvasively and inexpensively detect colorectal cancer (Photo courtesy of Pexels)

Novel Blood Test Could Detect Early-Onset Colorectal Cancer

Colorectal cancer is the fourth most common cancer, according to the U.S. Centers for Disease Control and Prevention. The rate of colon or rectal cancers in people younger than 50 years old has been on... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.